Abhishek Kumar Sen

Mr. Abhishek Kumar Sen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2022 in Metabolic Engineering Communications
Verified
Journal Article
Open access
AAAlexandra M. Adams
Alexandra M. Adams
NANicholas A. Anas
Nicholas A. Anas
ASAbhishek Kumar Sen
Abhishek Kumar Sen
JHJordan D. Hinegardner-Hendricks
Jordan D. Hinegardner-Hendricks
POPhilip J. O’dEll
Philip J. O’dEll
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address this limitation, we first developed a novel E. coli platform for the rapid and scalable production of gram-scale amounts of norbaeocystin. Through this process we compare the genetic and fermentation optimization strategies to that of a similarly constructed and previously reported psilocybin producing strain, uncovering the need for reoptimization and balancing upon even minor genetic modifications to the production host. We then perform in vivo measurements of head twitch response to both biosynthesized psilocybin and norbaeocystin using both a cell broth and water vehicle in Long-Evans rats. The data show a dose response to psilocybin while norbaeocystin does not elicit any pharmacological response, suggesting that norbaeocystin and its metabolites may not have a strong affinity for the serotonin 2A receptor. The findings presented here provide a mechanism to source norbaeocystin for future studies to evaluate its disease efficacy in animal models, both individually and in combination with psilocybin, and support the safety of cell broth as a drug delivery vehicle.

23 May 2023 in Metabolic Engineering
Verified
Journal Article
Closed access
LFLucas M. Friedberg
Lucas M. Friedberg
ASAbhishek Kumar Sen
Abhishek Kumar Sen
QNQuynh Nguyen
Quynh Nguyen
GTGabriel P. Tonucci
Gabriel P. Tonucci
EHElle B. Hellwarth
Elle B. Hellwarth
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones

16 April 2025 in Metabolic Engineering
Verified
Journal Article
Open access
MKMadeleine R. Keller
Madeleine R. Keller
MMMadeline G. McKinney
Madeline G. McKinney
ASAbhishek Kumar Sen
Abhishek Kumar Sen
FGFelicia G. Guagliardo
Felicia G. Guagliardo
EHElle B. Hellwarth
Elle B. Hellwarth
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
Psilocybin, the prodrug to the psychoactive compound in 'magic' mushrooms, is currently being studied in clinical trials as a treatment for severe mental health conditions, such as depression and anxiety. Previous reports of psilocybin biosynthesis as reconstituted in E. coli reported maximum titers of 1.16 g/L, exclusively using genes from the most common recreationally used mushroom, Psilocybe cubensis. This study explores the effect of gene species variation on psilocybin and baeocystin production using various exogenous genes sourced from psilocybin-producing mushrooms Psilocybe cubensis, Psilocybe cyanescens, Panaeolus cyanescens, and Gymnopilus dilepis. The psiD and psiK genes sourced from P. cubensis demonstrated unequivocally superior performance, while psiM showed varied production levels of psilocybin and the pathway intermediate baeocystin with changes in gene source. Strains containing a psiM gene sourced from Psilocybe cyanescens demonstrated a higher degree of baeocystin selectivity as compared to other psiM genes, demonstrating a key difference between species. Most notably, the strain Gymdi30, containing psiM sourced from G. dilepis, achieved a psilocybin titer of 1.46 ± 0.13 g/L, the highest reported to date. Comparative proteomic analysis of Gymdi30 during periods of high and low productivity was also performed to investigate bottlenecks in cellular metabolism, which could be limiting strain performance. This work represents a significant improvement in psilocybin biosynthesis, a key step towards the development of a biosynthetic manufacturing route for psilocybin.

14 June 2026 in Metabolic Engineering
Verified
Journal Article
Open access
ZAZachary N. Abrahms
Zachary N. Abrahms
MMMohammad Majdi
Mohammad Majdi
SMSiena M. Madsen
Siena M. Madsen
CMChloe J. Morton
Chloe J. Morton
ASAbhishek Kumar Sen
Abhishek Kumar Sen
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
Stable, high-level biosynthesis of complex natural products requires precise control of heterologous pathway expression, yet transcriptional architectures optimized on plasmids often fail when transferred to the chromosome. Here, we present ePathIntegrate, a genome-centric pathway engineering strategy that leverages CRISPR-associated transposases (CASTs) to integrate and rebalance multigene metabolic pathways in Escherichia coli. Direct genomic transfer of plasmid-optimized psilocybin and N,N-dimethyltryptamine (DMT) pathways resulted in a loss of productivity, driven by context-dependent promoter behavior. To address this, we developed and characterized a library of mutant T7 promoters that restore mid-range transcriptional control on the genome. Applying ePathIntegrate enabled re-optimization of both pathways, yielding genome-encoded strains that achieve 1.88 g/L psilocybin and 1.62 g/L DMT in fed-batch bioreactors. Whole-genome sequencing of CAST-mediated strains further revealed (i) precise on-target integration, (ii) some off-target pathway integrations, and (iii) small mutations in a subset of strains, highlighting both the power and limitations of CAST-mediated strain engineering.